27 papers · ranked by Valyu relevance
Hashem O. Alsaab, Samaresh Sau, Rami Alzhrani, Katyayani Tatiparti + 3 more
'Ketki Bhise' 'Sushil K. Kashaw' 'Arun K. Iyer'] Several cancers are highly refractory to conventional chemotherapy. The survival of tumors in several cases is assisted by checkpoint immunomodulation to maintain the imbalance between immune surveillance and cancer cell proliferation. Check point antibody inhibitors…
Young-Jun Park, Da-Sol Kuen, Yeonseok Chung
Recent advances in the understating of tumor immunology suggest that cancer immunotherapy is an effective treatment against various types of cancer. In particular, the remarkable successes of immune checkpoint-blocking antibodies in clinical settings have encouraged researchers to focus on developing other various…
Weijie Ma, Barbara M. Gilligan, Jianda Yuan, Tianhong Li
Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1) have demonstrated acceptable toxicity, promising clinical responses, durable disease control, and…
Mesude Bicak, Cansu Cimen Bozkus, Nina Bhardwaj
In the late 1800s, observations that bacterial infections could lead to tumor regression and that the immune system could recognize and eliminate precancerous cells, later proved by the identification of lymphocytes in the 1950s, shepherded a new era of cancer immunology and immunotherapy. Subsequently, the discoveries…
Pornpimol Charoentong, Francesca Finotello, Mihaela Angelova, Clemens Mayer + 4 more
The Cancer Genome Atlas revealed the genomic landscapes of common human cancers. In parallel, immunotherapy with checkpoint blockers is transforming the treatment of advanced cancers. As only a minority of the patients is responsive to checkpoint blockers, the identification of predictive markers and the mechanisms of…
Lu Yu, Minghan Sun, Qi Zhang, Qiao Zhou + 1 more
With the goal of harnessing the host’s immune system to provide long-lasting remission and cures for various cancers, the advent of immunotherapy revolutionized the cancer therapy field. Among the current immunotherapeutic strategies, immune checkpoint blockades have greatly improved the overall survival rates in…
Kamran Kaveh, Feng Fu
Immune checkpoint therapy is one of the most promising immunotherapeutic methods that are likely able to give rise to durable treatment response for various cancer types. Despite much progress in the past decade, there are still critical open questions with particular regards to quantifying and predicting the efficacy…
Kavita Iyer, Julian Ivanov, Rumiana Tenchov, Krittika Ralhan + 4 more
Rapid and sustained growth in the field of immuno-oncology has resulted in expansion of available scientific literature. Gaining valuable insights and establishing deep and often hidden meaningful connections in such a large body of work is the need of the hour. In this report we summarize our findings from a novel…
Rashmi P Mohanty, Yuting Pan, Mae M Lewis, Melissa Soto + 3 more
Tumor extracellular matrix (ECM) forms a net negative charged network that interacts with and hinders the transport of molecules partly based on electrostatic interactions. The focus on drug delivery in solid tumors has traditionally been on developing neutral charge coatings to minimize interactions with the ECM for…
Dinglin Liu, Haoyue Xiao, Ying Xiang, Dian Zhong + 3 more
'Yunfei Wang' 'Weijia Zhang'] In recent years, immune checkpoint blockades (ICBs) have made rapid progress in the field of cancer treatment, providing significant therapeutic effects and survival benefits, especially in patients with advanced refractory tumors. PD-1/PD-L1 blockade is one of the most widely used ICBs.…
Alexander Muacevic, John R Adler, Duncan Simmons, Eddy Lang
Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmable cell death protein 1 (PD-1)/PD-L1 have shown antitumor activity in cancers such as melanoma, non-small cell lung cancer, renal cell carcinoma, and urothelial cancer. Certain checkpoint inhibitors have been…
Collin Y. Zheng, Peter Kim
We introduce a set of ordinary differential equations (ODE) that qualitatively reproduces delayed responses observed in immune checkpoint blockade therapy (e.g. anti-CTLA-4 Ipilimumab). This type of immunotherapy has been at the forefront of novel and promising cancer treatments over the past decade and was recognised…
Rachel S Sousa, Shannon N Geels, Claire Murat, Alexander Moshensky + 3 more
The immune system can eradicate cancer, but various immunosuppressive mechanisms active within a tumor curb this beneficial response. However, unraveling the effects of multimodal interactions between tumor and immune cells and their contributions to tumor control using an experimental approach alone is time- and…
Yixuan Wang, Daniel Bergman, Erica Trujillo, Alexander T. Pearson + 2 more
Immunotherapy has dramatically transformed the cancer treatment landscape largely due to the efficacy of immune checkpoint inhibitors (ICIs). Although ICIs have shown promising results for many patients, the low response rates in many cancers highlight the ongoing challenges in cancer treatment. Cytotoxic T lymphocytes…
Dobrin Draganov, Zhen Han, Nitasha Bennett, Darrell J. Irvine + 1 more
We show that treatment with the FDA-approved anti-parasitic drug ivermectin induces immunogenic cancer cell death (ICD) and robust T cell infiltration into breast tumors. As an allosteric modulator of the ATP/P2×4/P2×7 axis which operates in both cancer and immune cells, ivermectin also selectively targets…
Weizhi Wang, Limin Zhang
Blocking programmed cell death ligand 1 (PD-L1) in tumor cells is an effective therapy strategy to achieve immune system activation for tumor therapy, however only a few patients can benefit from it. Development of synergistic therapy with checkpoint PD-L1 blockade immunotherapy is beneficial to enhance antitumor…
Charles H. Earnshaw, Poppy Dunn, Shih-Chieh Chiang, Agrin Moeini + 20 more
Half of advanced melanoma patients fail to benefit from immune checkpoint blockade and novel treatments are urgently required. Testing topical medications used in other skin diseases for anti-cancer activity in an immunotherapy-resistant murine melanoma model, we counterintuitively found that glucocorticoids elicit…
Prageeth R. Wijewardhane, Krupal P. Jethava, Jonathan A Fine, Gaurav Chopra
The Programmable Cell Death Protein 1/Programmable Death-Ligand 1 (PD-1/PD-L1) interaction is an immune checkpoint utilized by cancer cells to enhance immune suppression. There exists a huge need to develop small molecules drugs that are fast acting, cheap, and readily bioavailable compared to antibodies.…
Chenghang Li, Haifeng Zhang, Xiulan Lai, Jinzhi Lei
The tumor-immune system plays a critical role in colorectal cancer progression. Recent preclinical and clinical studies showed that combination therapy with anti-PD-L1 and cancer vaccines improved treatment response. In this study, we developed a multiscale mathematical model of interactions among tumors, immune cells…
Authors not listed
Immuno-oncology, a rapidly evolving field at the forefront of cancer research, leverages the body’s immune system to fight cancer. In this follow up report, we extend our natural language processing (NLP)-based analysis to pinpoint the context of emergence of the previously identified emerging concepts. To achieve this…
Tibor Bakács, Katalin Kristóf, J.N. Mehrishi, Tamás Szabados + 3 more
'Csaba Kerepesi' 'Enikoe Regoes' 'Gábor Tusnády'] 1Department of Probability, Alfred Renyi Institute of Mathematics, The Hungarian Academy of Sciences, 1053 Budapest, Reáltanoda str. 13-15. Hungary; 2Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Robert-Koch-Str. 40…
Bérengère Salomé, John P. Sfakianos, Jorge Daza, Andrew Charap + 43 more
PD-1/PD-L1-blockade immunotherapies have limited efficacy in the treatment of muscle-invasive bladder cancer (MIBC) and metastatic urothelial carcinoma. Here, we show that KLRC1 (NKG2A) expression associates with improved survival and responsiveness to PD-L1 blockade immunotherapy in CD8A^high^ bladder tumors. The loss…
Li, Chenghang, Lei, Jinzhi
Mathematical oncology is a rapidly evolving interdisciplinary field that uses mathematical models to enhance our understanding of cancer dynamics, including tumor growth, metastasis, and treatment response. Tumorimmune interactions play a crucial role in cancer biology, influencing tumor progression and the…
Haidong Dong
Following antigen stimulation, the net outcomes of a T cell response are shaped by integrated signals from both positive co-stimulatory and negative regulatory molecules. Recently, the blockade of negative regulatory molecules (i.e. immune checkpoint signals) demonstrates promising therapeutic effects in treatment of…
Yixuan Wang, Daniel R. Bergman, Erica Trujillo, Andrea Ziblat + 5 more
Immune checkpoint inhibitors (ICIs), a class of immunotherapy, offer promising benefits but face challenges such as low response rates to be used as a broadly effective treatment for all patients. In this study, we use a set of ordinary different equation (ODE) models and bladder cancer in vivo data as a case study to…
Huanyu Shi, Haotian Tang, Yan Li, Danqi Chen + 7 more
Hematopoietic progenitor kinase 1 (HPK1) is a serine/threonine kinase that serves as the negative regulator of multiple immune signaling pathways. Genetic studies using HPK1 knockout and kinase-dead mice suggested that inhibiting HPK1 either alone or in combination with immune checkpoint blockade could be promising…
Authors not listed
Blinatumomab is an FDA-approved bispecific T Cell engager(BiTE) that binds CD3 on T cells and CD19 on B cells, redirecting cytotoxic T cell activity to malignant B cells. Blinatumomab has achieved clinical success in treating B-cell acute lymphoblastic leukemia(B-ALL), however, the structural and functional…